Promising research is being conducted on targets such as Flt3L and IL-24 in the treatment of PCa, but additional verification is necessitated to confirm their therapeutic efficacy.[51,52] Consequently, exploring the interaction mechanisms between different inflammatory cytokines and their impact on triggering immune responses are crucial for researching the etiology and prognosis of PCa. The gene discussed is FLT3LG; the disease is posterior cortical atrophy.